Foghorn Therapeutics
FHTX • NASDAQ
Foghorn Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Adrian H. Gottschalk, with a market cap of $264.2M.
CEOAdrian H. Gottschalk
Next Earnings
Upcoming earnings announcement for Foghorn Therapeutics
Date
Wednesday, May 13, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.31
Revenue Estimate
$8.4M
Earnings History
Past 12 earnings reports for Foghorn Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 11, 2026 | Q4 2025 | -$0.34Est: -$0.27 | -25.9% | $9.2MEst: $8.9M | +3.3% |  10-K |
| Nov 5, 2025 | Q3 2025 | -$0.25Est: -$0.30 | +16.7% | $8.2MEst: $6.9M | +17.4% | 10-Q |
| Aug 5, 2025 | Q2 2025 | -$0.28Est: -$0.31 | +9.7% | $7.6MEst: $7.3M | +3.4% | 10-Q |
| May 14, 2025 | Q1 2025 | -$0.30Est: -$0.24 | -25.0% | $6.0MEst: $5.5M | +9.2% | 10-Q |
| Mar 6, 2025 | Q4 2024 | -$0.23Est: -$0.27 | +14.8% | $2.9MEst: $8.1M | -64.9% | 10-K |
| Nov 4, 2024 | Q3 2024 | -$0.31Est: -$0.44 | +29.5% | $7.8MEst: $6.3M | +23.2% | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.45Est: -$0.65 | +30.8% | $6.9MEst: $6.0M | +14.0% | 10-Q |
| May 6, 2024 | Q1 2024 | -$0.59Est: -$0.63 | +6.3% | $5.1MEst: $6.9M | -26.9% | 10-Q |
| Mar 7, 2024 | Q4 2023 | -$0.57Est: -$0.76 | +25.0% | $5.8MEst: $4.6M | +24.9% | 10-K |
| Nov 2, 2023 | Q3 2023 | -$0.34Est: -$0.75 | +54.7% | $17.5MEst: $4.5M | +286.7% | — |
| Aug 4, 2023 | Q2 2023 | -$0.70Est: -$0.73 | +4.1% | $5.6MEst: $6.3M | -10.6% | 10-Q |
| May 8, 2023 | Q1 2023 | -$0.73Est: -$0.72 | -1.4% | $5.3MEst: $5.0M | +5.3% | — |